

# 2019 IN NUMBERS



## R&D portfolio

**46**

R&D projects

**23**

new chemical entities  
in DNDi's drug  
development pipeline

**>350,000**

chemical compounds  
screened for new drug  
potential



## Clinical trials

**18**

clinical trials in 6 disease areas  
at 59 sites in 20 countries

**2,710**

patients enrolled in active  
DNDi clinical studies

**51%**

of patients enrolled  
are children



## Maximizing the virtual model

**4.7:1**

ratio of partner vs DNDi FTEs\*

**15:1**

ratio of partner vs DNDi FTEs\* in Africa



## Support received

**EUR 51.4** MILLION

in multi-year funds secured

**EUR 6.2** MILLION

in-kind contributions and collaborative  
funding from partners



## Sharing knowledge

**45**

peer-reviewed scientific publications  
on DNDi's research

**96%**

published in open-access journals

**50%**

had a female lead or co-lead author

**76%**

had at least one author from a partner  
institution in an endemic country



## Strengthening capacities

**630**

people trained to support  
clinical research in Africa,  
Asia, and Latin America

**64%**

of all R&D partner FTEs\*  
are in Africa

\*Staff in full-time equivalents